Allschwil, Switzerland-based Idorsia Ltd recently announced its financial results for the first half of 2021, at which time its drug daridorexant for the treatment of insomnia under review with United States FDA, EMA, and Swissmedic.
The AAN presentation further quantifies the previously reported Phase 3 top-line results.
The randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of pitolisant in patients with PWS ages 6 to 65.
Read MoreKemPharm is investigating “KP1077” as a potential treatment for idiopathic hypersomnia (IH), a sleep disorder of excessive sleepiness.
Read MoreApnimed’s AD109 is dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity.
Read More“Six out of 10 sodium oxybate-eligible patients are not going on therapy today, with twice-nightly dosing being the primary reason cited.”
Read More
Inhibiting the production of hydrogen sulfide in rats resulted normal breathing patterns becoming gasping patterns.
Read More
“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read More
A patent proposes a new treatment method that targets the increased D1 receptor levels in RLS patients experiencing augmentation.
Read More
Emerging evidence suggests the gut microbiome can influence health and sleep quality through the brain-gut microbiome axis.
Read MoreThe expedited development plan includes a Phase 3 efficacy trial, which will be used to support the filing of an NDA for approval of AXS-12.
Read MoreIn the phase 1 trial, R-oxybutynin demonstrated a favorable PK profile and was well tolerated with no adverse events.
Read More
Jordan Dubow, MD, will be stepping down as chief medical officer of Avadel Pharmaceuticals to pursue another opportunity.
Read MoreThe collaboration brings Idorsia’s daridorexant and expertise in the science of the orexin system together with Syneos Health’s customer-facing sales expertise and track record.
Read MoreA new patient-reported outcome instrument was developed to assess daytime functioning in patients with insomnia and Idorsia included it in daridorexant’s Phase 3 program.
Read MoreIMB-115 is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor.
Read More